AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18763235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 18763235 — intervention group
Group type: COMPARATOR
Intervention: Next morning performance
Number of subjects: 16
Study 16809807 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin daily for 2 months
Number of subjects: 44
Study 16809807 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg simvastatin daily for 2 months
Number of subjects: 44
Study 16809807 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 44
Study 14986414 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistive torque system controlled by EMG signals
Number of subjects: 5
Study 14986414 — intervention group
Group type: COMPARATOR
Intervention: Able-bodied individuals
Number of subjects: 5
Study 10966532 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 30
Study 10966532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8980590 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (up to 4 annual doses)
Number of subjects: 948
Study 8980590 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (up to 10 doses at 6-month intervals)
Number of subjects: 948
Study 8980590 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (both regimens)
Number of subjects: 948
Study 7936988 — intervention group
Group type: EXPERIMENTAL
Intervention: New two-axial conformation technique
Number of subjects: 0
Study 7936988 — intervention group
Group type: COMPARATOR
Intervention: Old conformation technique
Number of subjects: 0
Study 7936988 — intervention group
Group type: COMPARATOR
Intervention: Two-opposed technique
Number of subjects: 0
Study 7936988 — intervention group
Group type: COMPARATOR
Intervention: Box technique
Number of subjects: 0
Study 2905711 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetamolol 15 mg
Number of subjects: 12
Study 2905711 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 12
Study 2905711 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 12
Study 2905711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29398050 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 285
Study 29398050 — intervention group
Group type: COMPARATOR
Intervention: Statin use
Number of subjects: 285
Study 28497511 — intervention group
Group type: EXPERIMENTAL
Intervention: Trainees who successfully lost/maintained weight
Number of subjects: 219
Study 28497511 — intervention group
Group type: EXPERIMENTAL
Intervention: Trainees who lost/regained weight
Number of subjects: 219
Study 28497511 — intervention group
Group type: COMPARATOR
Intervention: Patients who did not lose weight
Number of subjects: 219
Study 28497511 — intervention group
Group type: EXPERIMENTAL
Intervention: Female trainees who successfully lost weight
Number of subjects: 219
Study 26139745 — intervention group
Group type: EXPERIMENTAL
Intervention: GA plus epidural (study group)
Number of subjects: 86
Study 26139745 — intervention group
Group type: COMPARATOR
Intervention: GA only (control group)
Number of subjects: 86
Study 23221315 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline factors predictive of drinking patterns
Number of subjects: 143
Study 21205115 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Number of subjects: 30
Study 21205115 — intervention group
Group type: COMPARATOR
Intervention: Insulin aspart
Number of subjects: 30
Study 18458219 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (8-16 mg once daily)
Number of subjects: 257
Study 18458219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 16451284 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-burst oxygen therapy
Number of subjects: 40
Study 12664205 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic stabilization followed by rehabilitation
Number of subjects: 24
Study 12664205 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy of immobilization and rehabilitation
Number of subjects: 24
Study 11247199 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal oil massage
Number of subjects: 125
Study 11247199 — intervention group
Group type: EXPERIMENTAL
Intervention: Sesame oil massage
Number of subjects: 125
Study 11247199 — intervention group
Group type: EXPERIMENTAL
Intervention: Mustard oil massage
Number of subjects: 125
Study 11247199 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral oil massage
Number of subjects: 125
Study 11247199 — intervention group
Group type: COMPARATOR
Intervention: Control (no massage)
Number of subjects: 125
Study 7558363 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervitec varnish (1% chlorhexidine and thymol) applied at baseline, after 3-4 months, and after 8-9 months.
Number of subjects: 502
Study 7558363 — intervention group
Group type: COMPARATOR
Intervention: Control tooth (untreated).
Number of subjects: 502
Study 7558363 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervitec varnish application.
Number of subjects: 502
Study 7558363 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary mutans streptococci estimation.
Number of subjects: 502
Study 7558363 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque mutans streptococci estimation.
Number of subjects: 502
Study 2084744 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial screening
Number of subjects: 0
Study 2084744 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 366484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 100
Study 366484 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 100
Study 366484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31796225 — intervention group
Group type: EXPERIMENTAL
Intervention: LAIV4 2017-2018 (A/Slovenia)
Number of subjects: 200
Study 31796225 — intervention group
Group type: COMPARATOR
Intervention: LAIV4 2015-2016 (A/Bolivia)
Number of subjects: 200
Study 31796225 — intervention group
Group type: COMPARATOR
Intervention: Trivalent LAIV (LAIV3) 2015-2016 (A/Bolivia)
Number of subjects: 200
Study 31796225 — intervention group
Group type: EXPERIMENTAL
Intervention: A/Slovenia vaccine strain
Number of subjects: 200
Study 31796225 — intervention group
Group type: COMPARATOR
Intervention: A/Bolivia strain
Number of subjects: 200
Study 31640757 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS pathway
Number of subjects: 640
Study 31640757 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (non-ERAS group)
Number of subjects: 640
Study 28628269 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate extended-release oral suspension (MEROS) 60 mg under fed conditions
Number of subjects: 0
Study 28628269 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate extended-release oral suspension (MEROS) 60 mg under fasting conditions
Number of subjects: 0
Study 25894061 — intervention group
Group type: EXPERIMENTAL
Intervention: ICECAP-A (non-weighted scores)
Number of subjects: 0
Study 25894061 — intervention group
Group type: EXPERIMENTAL
Intervention: ICECAP-A (value-weighted scores)
Number of subjects: 0
Study 25894061 — intervention group
Group type: EXPERIMENTAL
Intervention: ICECAP-A
Number of subjects: 0
Study 25894061 — intervention group
Group type: COMPARATOR
Intervention: EQ-5D-3L
Number of subjects: 0
Study 23832498 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 203
Study 23832498 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin (GP)
Number of subjects: 203
Study 23832498 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR-TKI (second-line treatment)
Number of subjects: 203
Study 23832498 — intervention group
Group type: COMPARATOR
Intervention: Both groups (gefitinib and GP)
Number of subjects: 203
Study 21464401 — intervention group
Group type: EXPERIMENTAL
Intervention: PTK787/ZK 222584 (PTK/ZK) with FOLFOX4
Number of subjects: 855
Study 21464401 — intervention group
Group type: COMPARATOR
Intervention: Placebo with FOLFOX4
Number of subjects: 855
Study 21464401 — intervention group
Group type: EXPERIMENTAL
Intervention: PTK787/ZK 222584 (PTK/ZK) with FOLFOX4 in patients with high LDH
Number of subjects: 855
Study 19801201 — intervention group
Group type: EXPERIMENTAL
Intervention: SRS plus WBRT
Number of subjects: 58
Study 19801201 — intervention group
Group type: COMPARATOR
Intervention: SRS alone
Number of subjects: 58
Study 16760316 — intervention group
Group type: EXPERIMENTAL
Intervention: MCV (Meningococcal group C polysaccharide-protein conjugate vaccine)
Number of subjects: 95
Study 15052244 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 30
Study 15052244 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (Control)
Number of subjects: 30
Study 11442734 — intervention group
Group type: EXPERIMENTAL
Intervention: Convex toothbrush
Number of subjects: 25
Study 11442734 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel toothbrush
Number of subjects: 25
Study 11442734 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat trimmed toothbrush
Number of subjects: 25
Study 9014018 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical signs (liver enlargement, parotid swelling, retches and tremor in the morning, hoarseness)
Number of subjects: 492
Study 9014018 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological markers (serum GGT, ASAT, MCV, urate levels)
Number of subjects: 492
Study 7715916 — intervention group
Group type: EXPERIMENTAL
Intervention: lovastatin
Number of subjects: 150
Study 7715916 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin
Number of subjects: 150
Study 7715916 — intervention group
Group type: COMPARATOR
Intervention: fenofibrate
Number of subjects: 150
Study 2927328 — intervention group
Group type: EXPERIMENTAL
Intervention: 'Know Your Midwife' scheme
Number of subjects: 503
Study 2927328 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital care
Number of subjects: 503
Study 31004770 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance care planning intervention
Number of subjects: 460
Study 31004770 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 460
Study 28878452 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal support device (SSD)
Number of subjects: 20
Study 28878452 — intervention group
Group type: COMPARATOR
Intervention: Control group (bed rest in supine position)
Number of subjects: 20
Study 26475714 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment (ART) in children undergoing oncohematological treatment (E)
Number of subjects: 38
Study 26475714 — intervention group
Group type: COMPARATOR
Intervention: Atraumatic Restorative Treatment (ART) in children not undergoing oncohematological treatment (C)
Number of subjects: 38
Study 24432673 — intervention group
Group type: EXPERIMENTAL
Intervention: Fangfeng Tongsheng Granule (FTG) at a daily dose of 3 g, twice per day for 3 days.
Number of subjects: 324
Study 24432673 — intervention group
Group type: COMPARATOR
Intervention: Simulated agent granules at the same dose and dosage as FTG.
Number of subjects: 324
Study 24432673 — intervention group
Group type: EXPERIMENTAL
Intervention: Fangfeng Tongsheng Granule (FTG)
Number of subjects: 324
Study 24432673 — intervention group
Group type: COMPARATOR
Intervention: Simulated agent granules
Number of subjects: 324
Study 22019575 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic diagnostic headache diary (BDHD) used before the first visit to the headache centre for at least 1 month
Number of subjects: 626
Study 22019575 — intervention group
Group type: COMPARATOR
Intervention: Clinical interview alone without BDHD
Number of subjects: 626
Study 19771459 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCT
Number of subjects: 24
Study 16477923 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 96 mg daily
Number of subjects: 38
Study 16477923 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 16 mg daily
Number of subjects: 38
Study 16477923 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 38
Study 16477923 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 38
Study 14727749 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal brain perfusion SPECT data generated using Monte Carlo simulations
Number of subjects: 0
Study 14727749 — intervention group
Group type: EXPERIMENTAL
Intervention: Ictal brain perfusion SPECT data generated using Monte Carlo simulations
Number of subjects: 0
Study 14727749 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated data for inter-hemispheric asymmetry coefficients
Number of subjects: 0
Study 10601410 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (IVIg) 0.4 g/kg body weight on 5 consecutive days
Number of subjects: 10
Study 10601410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9108848 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphtheria-tetanus-pertussis toxoids vaccine
Number of subjects: 3450
Study 9108848 — intervention group
Group type: COMPARATOR
Intervention: Diphtheria-tetanus toxoids vaccine
Number of subjects: 3450
Study 7503952 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline infusion
Number of subjects: 15
Study 7503952 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran infusion
Number of subjects: 15
Study 3901391 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 43
Study 3901391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 29806788 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes self-management education (DSME) + peer leader diabetes self-management support (PL DSMS) (n = 119)
Number of subjects: 221
Study 29806788 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC) (DSME + traditional DSMS with no PL; n = 102)
Number of subjects: 221
Study 27253395 — intervention group
Group type: EXPERIMENTAL
Intervention: vLAB (virtual laboratory simulation)
Number of subjects: 189
Study 27253395 — intervention group
Group type: COMPARATOR
Intervention: Demonstration (live demonstration from a lab tutor)
Number of subjects: 189
Study 24691504 — intervention group
Group type: EXPERIMENTAL
Intervention: ClearVoice-low
Number of subjects: 46
Study 24691504 — intervention group
Group type: EXPERIMENTAL
Intervention: ClearVoice-medium
Number of subjects: 46
Study 24691504 — intervention group
Group type: EXPERIMENTAL
Intervention: ClearVoice-high
Number of subjects: 46
Study 24691504 — intervention group
Group type: COMPARATOR
Intervention: HiRes Fidelity 120
Number of subjects: 46
Study 24691504 — intervention group
Group type: EXPERIMENTAL
Intervention: ClearVoice
Number of subjects: 46
Study 21378086 — intervention group
Group type: EXPERIMENTAL
Intervention: Subacromial corticosteroid injection
Number of subjects: 117
Study 21378086 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with home exercises
Number of subjects: 117
Study 19440186 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of Delta9-THC and MDMA
Number of subjects: 16
Study 19440186 — intervention group
Group type: COMPARATOR
Intervention: MDMA alone
Number of subjects: 16
Study 19440186 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of MDMA and THC
Number of subjects: 16
Study 19440186 — intervention group
Group type: COMPARATOR
Intervention: THC alone
Number of subjects: 16
Study 19440186 — intervention group
Group type: COMPARATOR
Intervention: MDMA
Number of subjects: 16
Study 17727577 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 0
Study 17727577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14714107 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg every 12 h for 7-21 days
Number of subjects: 544
Study 14714107 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin 1 g every 12 h for 7-21 days
Number of subjects: 544
Study 11915093 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (monitor time)
Number of subjects: 28
Study 11915093 — intervention group
Group type: COMPARATOR
Intervention: On-site (real time)
Number of subjects: 28
Study 9141123 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy storing feet (ESF) - Otto Bock Dynamic Pro and Hanger Quantum
Number of subjects: 10
Study 9141123 — intervention group
Group type: COMPARATOR
Intervention: Conventional feet (CF) - Otto Bock Multi Axial and Otto Bock Lager
Number of subjects: 10
Study 9141123 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall preference
Number of subjects: 10
Study 8243022 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/day for 3 weeks, followed by 10 mg/day for 9 weeks
Number of subjects: 97
Study 8243022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 3308241 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 156
Study 3308241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 350144 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline hydrochloride capsules with various dispersity levels
Number of subjects: 0
Study 350144 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline hydrochloride capsules with magnesium carbonate and calcium salts
Number of subjects: 0
Study 350144 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline hydrochloride capsules
Number of subjects: 0
Study 31564125 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate blended collaborative care intervention
Number of subjects: 40
Study 31564125 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 40
Study 31564125 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group after six-month waiting period
Number of subjects: 40
Study 31113408 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching
Number of subjects: 0
Study 31113408 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 28290057 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum supplementation (Col), 20 g/day for 14 days
Number of subjects: 18
Study 28290057 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Plac)
Number of subjects: 18
Study 26196753 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer biolimus-eluting stent (BES)
Number of subjects: 2707
Study 26196753 — intervention group
Group type: COMPARATOR
Intervention: Durable polymer everolimus-eluting stent (EES)
Number of subjects: 2707
Study 23651846 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient infusion into mid-jejunum
Number of subjects: 20
Study 23651846 — intervention group
Group type: COMPARATOR
Intervention: Nutrient infusion into duodenum
Number of subjects: 20
Study 21865355 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone (AMIO-ON group)
Number of subjects: 83
Study 21865355 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone (AMIO-OFF group)
Number of subjects: 83
Study 20161528 — intervention group
Group type: EXPERIMENTAL
Intervention: Ask-Advise-Refer (AAR) protocol
Number of subjects: 10
Study 17160982 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor analysis for boys
Number of subjects: 400
Study 17160982 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor analysis for girls
Number of subjects: 400
Study 17160982 — intervention group
Group type: EXPERIMENTAL
Intervention: Central body fat distribution and centralized subcutaneous fat (factors 1 and 2)
Number of subjects: 400
Study 15067098 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotics (ciprofloxacin 200 mg and amoxicillin-clavulanate 375 mg every 8 h)
Number of subjects: 36
Study 15067098 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antibiotics (ceftazidime 1 g every 12 h)
Number of subjects: 36
Study 11444419 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (15 mg)
Number of subjects: 175
Study 11444419 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein (15 mg)
Number of subjects: 175
Study 11444419 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene (15 mg)
Number of subjects: 175
Study 11444419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 11367649 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongmai Jiangzhi Oral Liquid (TJOL)
Number of subjects: 41
Study 11367649 — intervention group
Group type: COMPARATOR
Intervention: Capsulae Oenoth Erae Biennisolei (COEB)
Number of subjects: 41
Study 7868490 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 10
Study 3248127 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate with medium calcium concentration (1.34 +/- 0.03 mmol/L)
Number of subjects: 7
Study 3248127 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate with low calcium concentration (1.02 +/- 0.02 mmol/L)
Number of subjects: 7
Study 3248127 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate with high calcium concentration (1.68 +/- 0.07 mmol/L)
Number of subjects: 7
Study 31995838 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 1239
Study 31995838 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 1239
Study 31995838 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 1 mg
Number of subjects: 1239
Study 31995838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1239
Study 29438463 — intervention group
Group type: EXPERIMENTAL
Intervention: DHP107 (200 mg/m2 orally twice daily days 1, 8, 15 every 4 weeks)
Number of subjects: 236
Study 29438463 — intervention group
Group type: COMPARATOR
Intervention: i.v. paclitaxel (175 mg/m2 day 1 every 3 weeks)
Number of subjects: 236
Study 29438463 — intervention group
Group type: EXPERIMENTAL
Intervention: DHP107
Number of subjects: 236
Study 29438463 — intervention group
Group type: COMPARATOR
Intervention: i.v. paclitaxel
Number of subjects: 236
Study 28051926 — intervention group
Group type: EXPERIMENTAL
Intervention: Complicated Grief Group Therapy (CGGT)
Number of subjects: 0
Study 24674297 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care with 40 HBOT sessions
Number of subjects: 275
Study 24674297 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 275
Study 22575624 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus‐eluting stent (SES)
Number of subjects: 112